Send us Fan Mail In Episode 3 of CBmE&U, hosts Sinead and Julian chat with Professor Roger Foo (Yong Loo Lin School of Medicine at National University of Singapore) about Project RESET. Roger answers questions about heart health issues in Asia, the positive and negative impacts of personalised medicine, bridging racial gaps in knowledge, and whether we have free will. Remember people, be savvy!
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_00The center presents a new podcast, CBMENU, a podcast devoted to promoting awareness and debate around controversial ethical issues in biomedicine. So welcome to the third episode of CBMENU. Today we've got Professor Roger Fu, the Vice Dean of Research, and the Zaid bin Sultan Al Nahan, Professor of Medicine.
SPEAKER_00I hope I got that right, here at the Yong Lin School of Medicine at NUS. Thank you for coming on our podcast, Roger.
SPEAKER_02Thanks, Julian. Thanks for having me.
SPEAKER_01So, Roger, thank you for coming. I have some quick questions to get to know you a little bit better. The first one, coffee or coffee?
SPEAKER_02Oh, coffee. Sunate, definitely coffee.
SPEAKER_01All right. Can I just ask, is this like a flat white or an espresso?
SPEAKER_02No, very black, nothing else in it. All the fruitful fragrance and aroma of how a coffee should be, which does not exist in Kopi, that's why it's coffee.
SPEAKER_01So does that does this mean you like batch brew and filter coffee?
SPEAKER_02Yeah, yeah, yeah. So every morning there is a routine of grinding the beans and putting it in a pour over, uh, weighing the uh amount of water that goes in and in the four to two ratio that makes the coffee taste better.
SPEAKER_01I'm so impressed. I recently went to the city.
SPEAKER_02But it does take you half an hour to do that.
SPEAKER_01It must be very therapeutic though, to go through that process.
SPEAKER_02Yeah, it's the routine, right? So it clears the mind for the day.
SPEAKER_01Thank you. Second question: What country would you like to travel to the most?
SPEAKER_02Yeah, so I'd say Egypt, which I haven't had the chance to, mostly because I'm really up for history. And I remember feeling so thrilled when in Greek Greece I managed to touch the walls of Mycenae. I don't know if you know this place called Mycenae that they say it's 3,000 years old, all the stones of this uh part of the ruins. And I really want to do the same with Egypt and the uh pyramids and all that, but just not had the chance and not quite brave enough to go.
SPEAKER_01Understandable. Final question, uh, my favorite question. What song would you sing at karaoke?
SPEAKER_02Shanid, my goodness. I I don't think I ever have found myself in a karaoke, to be honest. Um, so I when I was much younger uh and foolish uh and getting married, I was made to sing on stage uh for my wedding, and it was a Chinese song that I sang. I could tell you what it is, but it'll be very funny and strange.
SPEAKER_01Please go for it.
SPEAKER_02Uh it's something to do with the moon being round and shiny. Uh, in Chinese, it's yeah yang type your scene. So some of your viewers might understand that.
SPEAKER_01I will go away and do my research. Thank you.
SPEAKER_00Okay, Roger. Um, so I uh you want to go to Egypt, and you you know you've got the pyramids there. And here in Singapore, you're you're building a pyramid yourself. Uh I I think it was at the Shangri-La Hotel I I saw Minister Ong introducing your massively important national initiative, and and and you were there with a giant piece of ice and an ice pick. Uh and and you were talking about the iceberg of of cardiovascular disease. So tell us about Project Reset that you know is dealing with this iceberg and what what this iceberg is and what your your pick constitutes.
SPEAKER_02Yeah, thanks, Julian. So uh we came to a realization as a whole group of researchers in cardiovascular disease on the island that uh we've been spending all the last 10, 20 years studying disease in the hospital. So this is your tip of the iceberg. People with your heart attacks, strokes, um, full-blown diabetes. But actually, there is a lot of unknown disease in the rest of the population, people who haven't yet presented to the hospital. Uh, and yet all of that disease is quite uh scary if you think about it.
SPEAKER_0240% of our Singaporean adults uh are thought to have fatty liver disease. All of them kind of uh red flags that they are marching in the wrong direction. So the whole of Project Reset is set out to study these people under the iceberg, uh, apparently healthy, but actually not quite. We want to map out all of their metabolic disease, cardiovascular disease spectrum, where they are, in which stages they are, and so on, uh, and figure out whether they are subgroups of these people. And if they're in these different subgroups, what characterizes or what characterize these different subgroups, uh, and how we can pick up people from one group from the other and what we can do for them each differently?
SPEAKER_00Yeah, I mean, just before I pass on to Sinead, you know, it's uh incredibly ambitious and important thing. 40% of the population. Um, I I urge everyone to sign up to Project Reset. I tried to sign up myself, but they wouldn't let me on because I'm I'm not a permanent resident. Uh, sad. So um, I mean, you know, how important do you think it is for for the ordinary person to take part in this? Or what what sorts of people can take part in this?
SPEAKER_02Oh, yeah, very important, Julian. Again, thank you for the shout-out on this. But there is quite stringent criteria that we are imposing on on the project because it's not uh just all comers. So it's uh it's aimed at recruiting or enrolling 3,000 people specifically, and we think that we have to at least go through 10,000 or more to get to these 3,000, mostly because the criteria is quite stringent. You need to have uh a fair amount of cardiovascular risk. So there's something known as an ASCVD calculator that you can go online, doctors do that, when your primary care doctors see you, they do that.
SPEAKER_02Uh, it's a calculation of things like uh whether you have hypertension, how high is your cholesterol, whether there's family history, smoking, etc. So after all of that calculation, if you come up with a risk of 5% or more uh in the next 10 years of having a cardiac event, uh you're considered moderate to high risk. And these are the people we want for reset. So, Julian, you may not qualify for reset anyway, which would be a good thing. But if you do, or if anyone does, it really would be a good project to sign up to.
SPEAKER_01Okay. I have my first question for you. Um I was reading a little bit about your project, a very small amount. Um, and I was really intrigued in the way your research has highlighted the difference in Asian and non-Asian disease presentation and trajectories and how it's really poorly known how heart disease affects Singapore and Asians more broadly. And I was wondering whether you think that the research, the reset project will begin to balance that racial gap in medical knowledge, or if you think we still have a really long way to go.
SPEAKER_02Yeah, there is still quite a long way to go. I mean, it's it's usually with questions like this, uh whether you're looking at it from this angle or that, you know, half cup full or half cup empty, uh, at least we are making progress towards it. It really is a sense that in Southeast Asia the disease spectrum seems to be quite different uh from, let's say, the West. Uh, some statistics, for example, is that a lot of our heart attacks and strokes, even I discovered the other day, uh, happening in people in their 50s or uh younger even now uh than in the West.
SPEAKER_02Um I presented some early reset data in a meeting in Germany a few months ago. And uh right before me speaking was another professor speaking about heart attacks and so on, and his age group was 70s, so late 60s to 70s, we're at least 10 years younger. Uh, and apart from that, a lot of our uh heart failure patients that come through uh are presenting for the first time with heart failure. Whereas in the West, you might have already encountered a doctor for chest pain, uh, implying some blockages in the arteries in an earlier age, and then when you actually get heart failure, it's not surprising.
SPEAKER_02Whereas for a lot of us, we're presenting with heart failure at the outstart.
SPEAKER_00So you must have some hunches uh that you want to test in this uh project. What are your hunches for these differences between Asian populations and Western populations?
SPEAKER_02Yeah, thanks, Julian. So it's still very much along the lines that we have metabolic drivers here and maybe also the immune drivers, they're very intertwined, both of them, immune and metabolism. Uh, and for whatever reason, I think it's a mix between uh genetics, so nature, as well as nurture, whatever we're encountering in our environment. Um and these two drivers seem to be very high up in what's happening around here.
SPEAKER_01Just to follow up with that question, um, you know, it's well known that health and disease are significantly affected by nature, genes, um, but then also things like lifestyle and access to healthcare. I was wondering the extent to which a reset will be able to identify and understand the role of socio-environmental factors, you know, the nurture, as contributing to poorer heart health in Singapore and Asia more broadly.
SPEAKER_02Yeah, Sinead, that's a really nice talking point. I have to admit that um now that we're already quite actively uh and almost exponentially recruiting on reset, we're finding that the people, and not surprisingly, the people that step forward are not of the fullest spectrum of the socioeconomic groups you would think of, right, in Singapore. Um maybe it's to be expected, people who want to find out more about themselves are a bit more educated, a bit more well-read, and they're uh queuing up, knocking at the door to sign up for reset.
SPEAKER_02It's the people who are busy working, needing to um, you know, think about other things of uh living and sustenance, and they're not really that bothered to come to your reset research research program. So we have to find ways to even out and um and assess all of that uh more thoroughly, I think.
SPEAKER_01Will that be a limit to the study if you don't?
SPEAKER_02I think so, yeah. I the the tr the reality is that we do have three uh ethnicities, first of all, in Singapore, uh in different ratios, but a lot of this kind of research requires sufficient numbers to make the statistics hold together. So if you uh recruit equally 3,000 divided by three, then you end up diluting your statistics because there are things that you want to study per ethnic group. Um so it's not an easy game. There's a lot of trade-offs that's being discussed in the team.
SPEAKER_00So what what are you doing to try to get to these groups that that aren't coming forward for I mean, this is a general problem in research. People should understand that you know often, you know, it it's really those who are most disadvantaged who least take part in research and and so don't benefit from the from the results. I mean, what what are you doing to address that?
SPEAKER_02Yeah, the easy answer I'd say to that, Julian, is that thankfully we are not the only research project on the island that's covering this huge spectrum now of uh primary care and population health. There are other means to get to such data as well. Uh so for example, in our Western cluster and UHS, we're all on a unified uh electronical, uh electronic medical record system now, Epic. Uh, and through that system, a lot of cleaning up is being done. So we're actually seeing the full spectrum of the entire population through the whole socioeconomic um spectrum and pulling out all those data.
SPEAKER_02So, where we think reset will go is to build a really deep uh level of data set on this very specific group of people, and then we have to find means of extrapolating to whatever we can find uh in the real-world EMR records data.
SPEAKER_00So, you know, it's gonna run for five years, and let's assume it's as successful as you hope. Um, you know, what could the average Singaporean expect from what how would their life be different uh in virtue of having done um this this study?
SPEAKER_02Yeah, so so the way I see success, I've been thinking about this for quite long. Um maybe a few different things. One would be uh some set of markers that would be more accessible and uh significant. So it's reducing the dimensions of the full spectrum of everything we're measuring down to a select set of markers. There could be molecular markers, they could be some genetic markers, they could also be some lifestyle markers because each reset person is going to is getting a uh smartwatch.
SPEAKER_02Oh so yeah, exactly. Yeah, so everyone gets a smartwatch and they're encouraged to keep it on 24-7 for the next five years. We're also having a we have a budget to uh refresh the smartwatch if it breaks down. Um and from the smartwatch information, you're actually literally picking up dynamic information on what people are doing and how they're living lifestyle, um, sleep, etc. So a set of markers um that would be useful to pick up people most at risk and knowing them, knowing what they're most at risk of, because as I mentioned, some are for heart failure, some are for fatty liver, some are for blockages in arteries, etc.
SPEAKER_02Uh, and another would be because this is very much a discovery project uh than a uh initial epidemiology search for and trying to make a risk calculator project. So that's quite a different uh way of thinking. Because it's discovery, we think we may also come up with some new gene targets for uh new gene uh new therapies, new treatments, new molecules that can be targeted for uh different purposes. Uh, an example of a huge great success story is the whether you like it or not, the injections that people are using for uh obesity and at first diabetes and now obesity.
SPEAKER_02So those kind of um molecular targets might be quite interesting to might be quite a good success thing to come out of reset.
SPEAKER_00So we maybe we'll come back to sort of gene therapy later and and ozempic and these these uh weight loss drugs. But uh from what you say, it sounds like at the end of the project you might tell me, oh, Julian, you know, you've got a higher risk of of heart disease than you thought. Um, are there gonna be things that the these people who are given, you know, that have these markers and and and now realize that they're at greater risk than they thought. They're actually part of the part of the iceberg. I mean, are they gonna be able to do anything about it?
SPEAKER_02Yeah, yeah. So that's the beauty of also part of the reset project. Embedded within reset is a small randomized control trial RCT. We're taking 200 out of the 3,000 to carry out an RCT where we're doing intensive lifestyle. Yeah, randomized control trial. So the randomized control trial is to test out two uh sorry, 200 people in two arms, so 100 in each arm. Uh the test is on an intervention, call it an intervention, uh, of a lifestyle uh health coach plus some AI factored into an app uh to improve activity, uh sleep patterns, uh, and maybe some uh well-being factors as well.
SPEAKER_02So the whole notion upon that, on that, or underpinning that, uh, is that there are still lifestyle factors that can be used in some people's lives uh to improve their trajectories if you want them to avoid going to the tip of the iceberg.
SPEAKER_01I've um I'm fascinated by the fact that reset is focused primarily on preventative health. Um, because recognizing that, you know, once there once a health condition is there, there is only so much medicine can do. And so I'm fascinated because you know, preventing health conditions in people is no easy task. People are fully rational and generally cognizant of the wrong they're doing to their bodies, but the lack of will is often, and you know, the lifestyle reason, such as multiple jobs, um, stressful family situations, all of these things can prevent people, you know, pursuing the health goals they really want to do.
SPEAKER_01So, to what extent um, well, I was interested in to what extent this AI, this wearable AI technology, these lifestyle coaches, um, are going to be more about motivation or whether or not there's going to be some sub-level of nudging to get people to finally achieve the the goals that they they want to.
SPEAKER_02Yeah, Sinee. So here I start to, you're pushing me to wander into very uncertain territory for myself. I'm not a psychologist, I'm actually meant to be a molecular cell biologist. I do wonder how much we can bring from reset to this uh dimension, which is also why we've started working very closely with behavioral scientists, behavioral economists, even. So the good thing about our school, Julian will know this, is we're quite avid in bringing on board um behavioral scientists and uh psychology, social science perspective.
SPEAKER_02There is a very strong notion, at least on our campus community, that uh Singapore or as an academic system, academic health system, we've done a lot for healthcare and uh we're so good with healthcare now. And where the last mile could really be is this social aspect and behavioral aspect. If we manage to get a uh if we really wanted to bend the rest of the curve for uh health improvement, it is this last mile of social science.
SPEAKER_02Um, so Reset is working together with behavioral uh experts. There's a few professors in our campus, as I mentioned, and we're leveraging them to think about um how nudging can be placed into the randomized control trial we're carrying out. I'm also uh working with professors to think about this concept of early adoption. So uh there are some of us that are much more keen on new technology.
SPEAKER_02Uh so equally, there's some of us that are much more keen on knowing how to improve health for ourselves. So, this you imagine would be the people that are doing everything they can, improving their lifestyles, etc. Uh and how you recognize these people uh takes time if you want to uh interview them, spend questionnaires to look for these people. But there could be surrogate markers uh that can be used to identify these people. So we're trying to build a project where through reset we can map loads of different markers and find surrogate markers to uh identify who early adopters are for uh healthcare innovation.
SPEAKER_02It's not just the um uh taking up of the information, but actually also practicing it and maintaining it beyond just the taking up. So there's several dimensions to that, and we're working our way through understanding all of it.
SPEAKER_00I think you know what one of the things that fascinates me about project reset is is I see it as the tip of another iceberg. Um so the the and that iceberg is we're going to get more and more information about people with this big data and electronic health record that is being introduced in Singapore, huge amounts of of data about people's risk. Um and so we will get more and more fine-grained information about the sorts of diseases we'll suffer from, how long we will live, how well we'll live.
SPEAKER_00And it's a little bit like a devil's offer, where the devil offers to tell you when you're gonna die. Uh and a lot of people have, in the genetics literature, I'm sure you're familiar with this, have you know, worried about the anxiety that this sort of information causes, the mental health problems, fatalism. But on the other hand, there are medical interventions. You know, you're going to offer them diet and exercise and different behavioral interventions and perhaps even drugs.
SPEAKER_00Uh, and then there's also information that you can uh use to plan retirement or travel or family. Um but I think this raises a kind of new level of medicine where everyone's at risk and you actually if you like it's precision risk. You know precisely what more precisely what your risk is. Um, how do you see that phase of medicine as we move from populations to kind of individual risk and risk is ever present?
SPEAKER_00Do you do you see this as a good thing or do you are you concerned about it?
SPEAKER_02Uh definitely a good thing. I mean, I don't know about being too much concerned. This is something that I've brought up to my friends in insurance as well. They're being done out of a job. So as we get more and more precise, because insurance is about population statistics calculation at population level, but the whole notion of precision medicine and personalizes you're actually going to be able to predict that for a single person in himself. So, you know, insurance is um pointless moot. Uh I think this is the way the world is going, like it or not.
SPEAKER_02We really do have more and more capabilities, as now, especially now with the AI uh feature into it as well. There will come a day when all of what you just described there, Julian, is is possible.
SPEAKER_00Well, one one of the concerns about this whole field, which is which is called bioprediction, the use of biological markers, including genes, but you know, other information for about your body to predict disease is insurance. So the ordinary person is concerned that if they find out that they are at higher risk, now they're Not going to be able to obtain, for example, life insurance or other forms of insurance. I mean, what what's your response to that concern that people have?
SPEAKER_02Yeah, that's the whole point. Because the the way that research is going at the moment and all the kind of omics that we are doing, like you describe, is aiming towards being able to give someone a very precise and accurate prediction of whether they are going to have that on or not, a disease. And um the reason why insurance is there is to protect you from ever getting one or not getting that disease or not getting that disease. So there is a clash between the two. I I don't know how that would be resolved. I mean, insurance would become pointless, as I said, uh when the time comes when people know what they will be getting or not getting.
SPEAKER_00I don't want to kind of spend all uh you know the podcast on this issue, but and it's not something that I've thought about, but it it's it doesn't seem to me to be pointless because the point of insurance is to be able to compensate for or to provide support during adverse events, right? So say, you know, at the moment you think your risk of heart disease is 50%.
SPEAKER_02No, that's only because the risk prediction now is not accurate. But if you're so precise and accurate, which we which is where we're going to be one day.
SPEAKER_00Well, let's just say that you know, at the end of your project, I find out I'm not 50% likely to have a heart attack. I'm 80% likely. And what I want is, you know, if that doesn't mean I will certainly have a heart attack. Um, and if I die, I want my 18-month-old son to have enough money to go to the expensive schools in Singapore. So I want to take out life insurance, but now they say, oh, your risk isn't 50%. It's it's it's actually 80%. So, you know, your premium is not you know$10,000 a year, it's$30,000 a year.
SPEAKER_00So, you know, I I I don't see that it's going to make insurance obsolete because I still want my son to be able, if I die prematurely, um, to be able to go to school here. So I mean, I think that is quite worrying because you know the people who are lucky will actually not be pooling their risk with the people who are unlucky. So there's a concern of undermining of solidarity that there'll be a kind of hierarchy of people and it will will disadvantage the genetically uh you know unlucky.
SPEAKER_02Yeah, I really don't have an answer to that question. I'm glad it's not my problem.
SPEAKER_01We'll deal with that in our partnership. I think what that makes that more concerning though is it's not really just luck. Uh your health care outcomes, your health predictions are also based on your socioeconomic position. So, you know, if you already are predisposed to worse health care outcomes, your insurance will go significantly up, but those who are quite well off already and therefore have better health, their insurance will go down. But that's not, you know, that solidarity isn't there. We're no longer equal. In fact, we never were, but it's obvious now.
SPEAKER_02Well, I'm seeing disease as a balance between nature and nurture where you you are predisposed to something by all the things that you're currently set up with genetics, molecular, everything else. But if you did any change to your lifestyle, then you could be changing the changing the course of your uh likelihood of getting that disease XYZ. Um but the trouble in the future, I am thinking, is that AI could predict that even of whether you're getting there.
SPEAKER_02So that's where I start to see that insurance doesn't quite cover. I mean, I I'm not sure what people would be insuring against if you know exactly where you'd be going.
SPEAKER_01I've I've I think I've accepted in my head that this insurance question is far bigger than the podcast. And that we might need teams of people working on, you know, re-establishing, refiguring this out. I just had a thought about whether or not Reset will be testing for epigenetic changes. Um, and whether what that means is we might be able to start to, you know, use precise medicine to reverse those epigenetic changes.
SPEAKER_00So I just tell people what epigenetic changes are.
SPEAKER_01Would you do the ones?
SPEAKER_02So yeah, actually, the term epigenetics means um different things to different people. That's partly also the trouble that I I'm trying to figure out what the right answer to your question is. So we are definitely measuring uh molecules in the system that uh are known to change gene programs. And uh a lot of these molecules can be modified by drugs because the uh the by changing these molecules, you can then change gene programs and uh change the way the cells and tissues and organs behave.
SPEAKER_02So from that point of view, we are um measuring epigenetic profiles and epigenetic molecules.
SPEAKER_01So it's really whole genome and whole epigenome, so you can see.
SPEAKER_02Yeah, yeah, definitely. That's fascinating. There is also another aspect of epigenetics when some people use that term, they're thinking of uh some unknown mechanism that is um experienced by an individual that then gets passed on to subsequent generations. So that part of epigenetics, we're not uh really quite sure what what the underpinnings are or drivers are, so we're not actually touching that in reset.
SPEAKER_00Um so you're gathering these vast amounts of information about individuals, about different, particularly cardiovascular risks, but other risks, but inevitably you'll turn up other findings. So, you know, I come into this project, you know, say with a 10% chance of a heart attack, and you know, you you you do all these tests and you say, Oh no, Julian, actually we found you're, you know, also at risk of X. Now, what might X be? What what what else might you find out about people in this and and and what's going to be your approach to to that?
SPEAKER_02Yeah, Julia, I'm sitting up because we are actually finding that out already now. There are patients, or not patients, because these are perfectly healthy people or apparently healthy people, they are already showing signs of cognitive impairment. Uh, and they are not aware of it. Um, and they're uh this is alongside all the fatty liver and uh and blocked arteries they were also finding. Wow. I mean the whole Are you telling them? Yeah, so there is the part of the questionnaire that says to them, you know, do you want to know about incidental findings?
SPEAKER_02We're keeping a very close eye on the whole counselling process on this. Because this is a study on an apparently healthy person, right? So you are going to unearth things, which is what the whole project set up for.
SPEAKER_00I think you just say it's very early days and you just started to uncover this, and it's to be expected because not only do you have disease in your heart, you also have disease in your brain you didn't know about. Um I mean anecdotally, how do people take this?
SPEAKER_02Um I I think we so we have prepared them before, you know, in the consent process before the study started. That this is, you know, you're studying your brain, you're studying your liver, etc. etc. Uh so far, I think it's uh we have seen a few people already and brought them on board. We've also referred to uh neurologists for deeper analysis. I mean, it's still early days, they need further tests to I mean it's not manifest disease, so that's why uh are they gonna be able to do anything about it?
SPEAKER_02Yeah, yeah, I think so. So hence the uh the whole axiom about prevention better than cure, you know, finding it earlier.
SPEAKER_00I mean that gets me. I mean, again, this is a difficult question, and I I really don't expect you to to sort of and we certainly won't hold you to this answer, but I'm just trying to get a like uh a kind of an idea about what the magnitude of the sort of benefits on offer are for the ordinary person, yeah. So say, you know, I enter this program and I've got a 10% chance of having a stroke or a heart attack in the next 10 years or what five years or whatever it was, and and I do the things that you tell me to do. What what what would my chance of having those events change to?
SPEAKER_00How much impact could this have on my life?
SPEAKER_02Yeah, I I really can't tell you any fixed numbers to that. It's what we call residual risk uh or you know missing factors that we haven't uh and and we think there are a lot more, at least today, and then resets unearthing those other ones. But beyond that, there may be others too. So yeah, it's really hard to know.
SPEAKER_00I only have a couple more questions, but you mentioned these new weight loss drugs, um like Ozempic or Wegovni. Um, these are drugs based on semiglutide, which um enters the brain and apart from a changes brain activity, and a part of that reduces appetite. And you have quite striking um uh you know effects in terms of weight loss and you know, treatment of diabetes, reduction of cardiovascular risk, uh and really spectacular uh people basically lose huge amounts of weight and just don't want to eat.
SPEAKER_00It's been it's basically single-handedly resuscitated the Danish economy, the the Danish company that produces it. So a lot of the Hollywood superstars are on these drugs. I mean, what what what do you say to somebody who says, well, we should be putting you know Singaporeans on these, not just for the treatment of diabetes, but for prevention of cardiovascular risk? Because that's something we could do now. We don't need a five-year project. You know, there's data in now. You know, what's what's your response to this sort of you know, tsunami of enthusiasm for ZAMPIC?
SPEAKER_02Yeah, exactly. So people do wonder whether this is where project reset would go as well, if we find also targets like these and uh drugs get made and they're actually then uh showing potential usefulness for prevention. Uh it's so easy to think that um a drug will do it when asking people to exercise and nudging them doesn't actually get them over the line. Uh yeah, actually, I mean, great questions too, Julian. I I don't know exactly what the right answers to this is.
SPEAKER_02Um as a scientist, again, I would say that I've been really excited to see how uh the GRP1 reset tech and tech uh agonies have been so successful at uh creating weight loss and then also so revealing that um at the end of the day, uh dealing with obesity, or maybe the bigger word is metabolism, uh, is ending up driving so many different organs around the body. So it's not just like you say, uh diabetes, but actually also heart, brain, uh the signals on vascular dementia improving because of uh this medicine, kidney, uh liver for sure.
SPEAKER_02So metabolism is a huge driver for a lot of the ills that we're seeing uh on earth, planet Earth today. So this, as you say, this company's made really a lot out of it.
SPEAKER_00Yeah, my understanding of the literature on this is that it has spectacular benefits, but only while you take the drug. Once you stop, you put the weight back on, which means great for the company, you're on the drug for life. Um now that reduces people's eating and and uh you know their their feelings of fullness and social aspects of eating, but also it means that they're dependent on a drug in a way that they're not if they employ these lifestyle changes.
SPEAKER_00And I think this is another kind of change in the trajectory of medicine of putting people drug on drugs for life, or conditions like just what you put in your mouth, essentially. So some people will say this is over-medicalization, you know, of the human condition, that um is medicine gone too far, you know, having drugs now just because people can't stop eating. I mean, what do you say to that, to the sort of work that you're doing, that you're over-medicalizing?
SPEAKER_02Uh I again I would just fall back and say that I'm really excited by the science. So part of it is the discovery, you know, when people set out doing genome-wide as genome-wide association studies on things like obesity and um uh body sizes, uh, everyone thought that some of those gene targets would come out around metabolic genes, mitochondrial genes, genes that uh drive your um energy utilization, etc. But it turned out that a large proportion, maybe 80-90%, of the genes are actually genes that are expressed in the brain in the hypothalamus, dealing with appetite cessation uh when you feel full after you've eaten.
SPEAKER_02Some people uh have just eaten, but they're still uh happy to keep eating. And it really turned out that these are the genetic uh underpinnings and drivers of obesity, and hence the success of the um semaglutate and uh no, not semaglutate specifically, but the GRP1 receptacon is drug.
SPEAKER_00Aaron Powell So I wanted to just go back to this very striking, you know, um finding that when they looked for these genes for different body types, they weren't actually in the metabolism, they were in the brain. So, you know, maybe maybe this is a point to finish. But you know, one of the deepest questions in philosophy is whether free will exists and you know what it is, and um and what you've raised is this possibility that just how much we eat isn't so much a matter of choice, it's a matter of the genes we happen to inherit and the way our brain is is wired up.
SPEAKER_00You know, and I'm not expecting you to answer this sort of this millennia-old question about free will, but you know, as a person at the coalface that has to deal with people living, you know, deal l dealing with different lifestyle problems, lifestyle diseases, prevention of cardiovascular risk. You know, how much free will do you think people have when it comes to you know managing their disease? You know, what what how what's your you know, from the coalface sort of approach to this sort of issue of people's free will and responsibility?
SPEAKER_02My own conclusion is that we don't have free will. Free will is uh figment of imagination. So the moment you think that you have uh free will and decision-making power for yourself, you've already lost it. There's so much influence, isn't there? I mean, Julian, you'd be a better person to say about this social media, the uh society we the people that we hang around. There's no free will really.
SPEAKER_00So do you think I mean Singapore? I I love living in Singapore, and you know, it's a fantastic experiment. And one of the things you do have is a sort of nimble and uh willing-to-act government. Do you think, given that we don't have free will, the government should be more involved in forming policies, legislating, you know. Um, for example, you know, I th I was at also at the the your launch, I think it was there that Minister Ong mentioned a kind of you know, providing alternative to to sodium and salt to you know reduce the problems from hawker food.
SPEAKER_00Um, but you know, the government could increase, include a you know, massive sugar tax that would reduce people's consumption, or it could just ban certain amounts of sugar. Do you think the government should be taking a more active role in preventing these diseases?
SPEAKER_02Is there not a balance between uh being too much a nanny state versus uh giving someone too much liberty and going off and getting themselves overly fat and overly salted? Um I don't know. Maybe there must be some sweet spot somewhere in between. I mean people should have people should be um educated enough to make the right choices for themselves and be responsible.
SPEAKER_00They they don't have any free will, so it's important educating if they don't know.
SPEAKER_02Where is the choice coming from?
SPEAKER_01Um I think we'll probably leave it there. I think those are questions maybe for a book or several books or um a volume of books for us to answer. Um I've really enjoyed this chat today with you, Roger and Julian too, I believe. Um so thank you so much for coming on this podcast. You're welcome back anytime. Very great. Maybe in five years. Roger will not be coming back. Thank you.
SPEAKER_00Thank you. Thanks very much. Thanks for listening to our new podcast. Subscribe online and tune in every first of the month. In the meantime, listen to CBME and U and be stabby.
Send us Fan Mail We spend much of our lives searching for meaning. Some of us look for it at work. Some in our families and friends. Some look for it at an overpriced spiritual retreat in Bali where some dude named...
Send us Fan Mail In some insurance scheme, you might be required to pay more because you are more prone to disability. In another, you may have to pay more because you're a woman (and are statistically likely to live...
Send us Fan Mail Did you know that genomic sequencing can now screen newborns for hundreds of rare conditions right at birth? That looking too closely at our DNA might actually cause more anxiety than answers? And is...
Send us Fan Mail Did you know that over 80% of people who give birth experience an injury? That anywhere between 30 and 50% of people who give birth find it traumatic? And that up to 15% of people experience PTSD from...
Send us Fan Mail Could a blob of cells in a petri dish one day think? Feel? Have rights? In this episode, Professor Insoo Hyun (Harvard Medical School, one of the world's leading experts on the ethics of stem cell and...